AXL inhibition via AXL knockdown studies or through the use of AXL tyrosine kinase inhibitors was able to reverse acquired resistance and 20% of primary tumor samples demonstrated significant upregulation of AXL upon the development of in vivo resistance as compared to pre-treatment samples [41, 104]. This evidence concerns the gene AXL and neoplasm.